We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · May 05, 2022

Ribociclib Plus Letrozole in Male Patients With HR+/HER2− Advanced Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial
Breast Cancer Res Treat 2022 Feb 25;[EPub Ahead of Print], M Campone, M De Laurentiis, C Zamagni, I Kudryavcev, M Agterof, U Brown-Glaberman, M Palácová, S Chatterjee, L Menon-Singh, J Wu, M Martín

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading